Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.

Literature DB >> 27081179

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.

Kathy L McGraw¹, Johnny Nguyen², Rami S Komrokji¹, David Sallman¹, Najla H Al Ali¹, Eric Padron¹, Jeffrey E Lancet¹, Lynn C Moscinski², Alan F List¹, Ling Zhang³.

Abstract

Entities: Disease Gene

Keywords: IHC; TP53; myelodysplastic syndromes

Mesh：

Substances：

Year: 2016 PMID： 27081179 PMCID： PMC4967580 DOI： 10.3324/haematol.2016.143214

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

9 in total

1. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Authors: Leonie Saft; Mohsen Karimi; Mehran Ghaderi; András Matolcsy; Ghulam J Mufti; Austin Kulasekararaj; Gudrun Göhring; Aristoteles Giagounidis; Dominik Selleslag; Petra Muus; Guillermo Sanz; Moshe Mittelman; David Bowen; Anna Porwit; Tommy Fu; Jay Backstrom; Pierre Fenaux; Kyle J MacBeth; Eva Hellström-Lindberg
Journal: Haematologica Date: 2014-03-28 Impact factor: 9.941

2. Ubiquitination and degradation of mutant p53.

Authors: Natalia Lukashchuk; Karen H Vousden
Journal: Mol Cell Biol Date: 2007-10-01 Impact factor: 4.272

3. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

Authors: D A Sallman; R Komrokji; C Vaupel; T Cluzeau; S M Geyer; K L McGraw; N H Al Ali; J Lancet; M J McGinniss; S Nahas; A E Smith; A Kulasekararaj; G Mufti; A List; J Hall; E Padron
Journal: Leukemia Date: 2015-10-30 Impact factor: 11.528

4. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

Authors: Austin G Kulasekararaj; Alexander E Smith; Syed A Mian; Azim M Mohamedali; Pramila Krishnamurthy; Nicholas C Lea; Joop Gäken; Coralie Pennaneach; Robin Ireland; Barbara Czepulkowski; Sabine Pomplun; Judith C Marsh; Ghulam J Mufti
Journal: Br J Haematol Date: 2013-01-09 Impact factor: 6.998

5. Clinical effect of point mutations in myelodysplastic syndromes.

Authors: Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal: N Engl J Med Date: 2011-06-30 Impact factor: 91.245

6. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.

Authors: Sanam Loghavi; Alyaa Al-Ibraheemi; Zhuang Zuo; Guillermo Garcia-Manero; Mariko Yabe; Sa A Wang; Hagop M Kantarjian; Cameron C Yin; Roberto N Miranda; Raja Luthra; L Jeffrey Medeiros; Carlos E Bueso-Ramos; Joseph D Khoury
Journal: Br J Haematol Date: 2015-06-30 Impact factor: 6.998

Review 7. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.

Authors: Ling Zhang; Eric Padron; Jeffrey Lancet
Journal: Leuk Res Date: 2014-11-06 Impact factor: 3.156

Review 8. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors: Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal: Blood Date: 2011-02-07 Impact factor: 22.113

9. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

Authors: Rafael Bejar; Kristen E Stevenson; Bennett Caughey; R Coleman Lindsley; Brenton G Mar; Petar Stojanov; Gad Getz; David P Steensma; Jerome Ritz; Robert Soiffer; Joseph H Antin; Edwin Alyea; Philippe Armand; Vincent Ho; John Koreth; Donna Neuberg; Corey S Cutler; Benjamin L Ebert
Journal: J Clin Oncol Date: 2014-08-04 Impact factor: 44.544

9 in total

10 in total

1. TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies.

Authors: Marianna B Ruzinova; Yi-Shan Lee; Eric J Duncavage; John S Welch
Journal: Haematologica Date: 2019-02-21 Impact factor: 9.941

2. Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia.

Authors: Nana Arai; Mayumi Homma; Maasa Abe; Yuta Baba; So Murai; Megumi Watanuki; Yukiko Kawaguchi; Shun Fujiwara; Nobuyuki Kabasawa; Hiroyuki Tsukamoto; Yui Uto; Hirotsugu Ariizumi; Kouji Yanagisawa; Norimichi Hattori; Bungo Saito; Eisuke Shiozawa; Hiroshi Harada; Toshiko Yamochi-Onizuka; Tsuyoshi Nakamaki; Masafumi Takimoto
Journal: Int J Hematol Date: 2019-03-07 Impact factor: 2.490

Review 3. Patterns of mutations in TP53 mutated AML.

Authors: John S Welch
Journal: Best Pract Res Clin Haematol Date: 2018-09-20 Impact factor: 3.020

4. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.

Authors: Weerapat Owattanapanich; Julia Herzig; Nikolaus Jahn; Ekaterina Panina; Theera Ruchutrakool; Smith Kungwankiattichai; Surapol Issaragrisil; Hartmut Döhner; Konstanze Döhner
Journal: Ann Hematol Date: 2021-04-10 Impact factor: 3.673

5. Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy.

Authors: Francesca Ferraro; Agata Gruszczynska; Marianna B Ruzinova; Christopher A Miller; Mary Elizabeth Percival; Geoffrey L Uy; Iskra Pusic; Meagan A Jacoby; Mathew J Christopher; Miriam Y Kim; Peter Westervelt; Amanda F Cashen; Mark A Schroeder; John F DiPersio; Camille N Abboud; Lukas D Wartman; Feng Gao; Daniel C Link; Timothy J Ley; John S Welch
Journal: Haematologica Date: 2022-07-01 Impact factor: 11.047